METHYLNALTREXONE BROMIDE (methylnaltrexone bromide) by Teva is mu-opioid receptor. Approved for opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer, its treatment and 4 more indications. First approved in 2024.
Drug data last refreshed 18h ago
mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the…
Worked on METHYLNALTREXONE BROMIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide